Glucose oxidase induces mobilization of long-term repopulating hematopoietic cells in mice

Han-Sol So | Min-Guk Kim | Jeong-Chae Lee | Sung-Ho Kook

1Department of Bioactive Material Sciences, Research Center of Bioactive Materials, Jeonbuk National University, Jeonju, South Korea
2Cluster for Craniofacial Development and Regeneration Research, Institute of Oral Biosciences and School of Dentistry, Jeonbuk National University, Jeonju, South Korea

Correspondence
Jeong-Chae Lee, PhD, Institute of Oral Biosciences and School of Dentistry, Jeonbuk National University, Jeonju 54896, South Korea.
Email: leejc88@jbnu.ac.kr
Sung-Ho Kook, PhD, Department of Bioactive Material Sciences, Jeonbuk National University, Jeonju 54896, South Korea.
Email: kooksh@jbnu.ac.kr

Funding information
National Research Foundation of Korea funded by the Ministry of Science, Information and Communications Technology and Future Planning, Republic of Korea, Grant/Award Numbers: 2021R1A2C2006032, 2019R1A2C2084453

Abstract
Hematopoietic stem progenitor cells (HSPCs) mobilized to peripheral blood, rather than those remaining in the bone marrow (BM), are commonly used as stem cell source in the clinic. As reactive oxygen species (ROS) are suggested as mediator of HSPC mobilization, we examined the impacts of glucose oxidase (GO) on peripheral mobilization of BM HSPCs and the associated mechanisms. Intravenous injection of GO induced HSPC mobilization even by single treatment, and the GO-mobilized cells maintained their long-term reconstituting and differentiating potentials in conditioned recipients. GO-injected mice lived a normal life without adverse effects such as stem cell senescence, hematopoietic disorders, and blood parameter alteration. The mobilization effect of GO was even evident in animal models showing poor mobilization, such as old, 5-fluorouracil-treated, or alendronate-treated mice. Importantly, combined injection of GO with granulocyte colony-stimulating factor (G-CSF) and/or AMD3100 enhanced more greatly HSPC mobilization than did G-CSF, AMD3100, or both. The GO-stimulated HSPC mobilization was almost completely attenuated by N-acetyl-L-cysteine treatment. Collectively, our results not only highlight the potential role of GO in HSPC mobilization via ROS signaling, but also provide a GO-based new strategy to improve HSPC mobilization in poorly mobilizing allogeneic or autologous donors via combination with G-CSF and/or AMD3100.

KEYWORDS
hematopoietic stem cell transplantation, long-term repopulation, mobilization, self-renewal

Significance statement
The authors demonstrate for the first time that glucose oxidase (GO) promotes peripheral mobilization of hematopoietic stem progenitor cells (HSPCs) that maintain their functions in conditioned recipients without hematopoietic and immunological disorders. This study highlights mobilizing potential of GO even in mice exhibiting poor HSPC mobilization and provides an evidence that the efficacy of commonly used mobilizers is synergistically enhanced in combination with GO without adverse events.
1 | INTRODUCTION

In recent years, bone marrow (BM) transplantation has been replaced to the transplantation of mobilized peripheral blood (PB) stem cells (PBSCs) in many cases of cancer patients. PBSCs engraft and provide faster recovery of white blood cell (WBC) count better than BM-derived hematopoietic stem progenitor cells (HSPCs), thereby protecting patients from the risk of infection during the early post-transplantation period.1-3

Reactive oxygen species (ROS) are associated with HSPC mobilization induced by stem cell mobilizers, granulocyte colony-stimulating factor (G-CSF), and AMD3100.4,5 However, whether ROS are a determinant in peripheral mobilization of HSPCs still remains to be elucidated. Here we explore the impacts of glucose oxidase (GO) itself or in combination with the commonly used mobilizers on HSPC mobilization along with the associated mechanisms using various types of animal models. GO, approved by the federal Food and Drug Administration, is an oxidoreductase that converts glucose into glucuronic acid and hydrogen peroxide. Differently to hydrogen peroxide, GO induces a mild and prolonged generation of ROS and modulates intracellular redox state.6-8 Fungal GO is also widely applied in various areas of food industry.9 The results of our study show potential roles of GO on HSPC mobilization. This study also demonstrates that the use of GO enhances synergistically the efficacy of G-CSF and AMD3100 without adverse effects.

2 | MATERIALS AND METHODS

2.1 | Animals and treatment

The Animal Welfare Committee of Jeonbuk National University approved all experimental procedures. Unless otherwise specified, this study used BALB/c mice (8-week-old, Orient Bio, Daejeon, South Korea), and chemicals were purchased from Sigma-Aldrich Co. LLC (St. Louis, Missouri). Mice received intravenous injection of GO (0.250 U/g) dissolved in 0.05 M sodium acetate via tail vein for single or consecutive days (2-5 days). Mice received subcutaneous injection of G-CSF (250 μg/kg, Amgen, Thousand Oaks, California) for five consecutive days, AMD3100 (5 mg/kg) for single treatment, or both. To evaluate HSPC mobilization, PB was collected from mice 4 hours after the last injection of GO or the mobilizers. To explore the impact of GO on mobilizer-induced HSPC mobilization, mice that had received subcutaneous injection of G-CSF and/or AMD3100 were administered with GO via intravenous injection 12 hours before PB collection. To determine whether GO-stimulated HSPC mobilization is mainly due to ROS signaling, mice were subcutaneously administered with N-acetyl-L-cysteine (NAC; 100 mg/kg) 10 minutes before GO injection. We also examined the impact of GO on HSPC mobilization using old mice (12-month-old) or the mice that received HSPC mobilizing disturbers such as 5-fluorouracil (5-Fu), alendronate (ALN), or streptozotocin (STZ).10 To produce the poor HSPC mobilizing models, mice were intraperitoneally treated with single injection of 5-Fu (50 mg/kg), 3-week consecutive injection of ALN (0.25 mg/kg), or single injection of STZ (150 mg/kg). The 5-Fu- and ALN-injected mice received a single GO (0.250 U/g) injection 3 weeks and 4 hours after the reagent injection, respectively. Diabetic phenotype in STZ-injected mice was evaluated 7 days after the injection, in which the mice showing more than 300 mg/dL of blood glucose level were used for GO treatment.

2.2 | Flow cytometric analysis

The frequencies of Lin−c-Kit+ (LK) and CD150+CD48− LK cells in PB and BM were assessed by multicolor flow cytometry (BD Aria, BD Bioscience, Franklin Lakes, New Jersey) at the Center for University-Wide Research Facilities of Jeonbuk National University. Those cells were phototypically gated and further analyzed using the FlowJo software program (FLOWJO, Ashland, Oregon). LK and CD150+CD48+ LK cells from PB and BM were phototypically identified using the following antibodies (all antibodies were purchased from BD Biosciences [San Jose, California], unless specified otherwise): lineage markers phycoerythrin (PE)-Cy7-conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD45R, anti-c-Kit; PerCP/Cy5.5-conjugated anti-CD150 (eBioscience, Waltham, Massachusetts); and APC-Cy7-conjugated anti-CD48. Gr-1+CD11b+ granulocytes in BM were measured using PE-Cy7/FITC-conjugated antibodies. CXCR4+ cells were assessed using PE-conjugated anti-CXCR4 antibody (eBioscience). We also evaluated whether GO injection induces cellular oxidative stress and senescence several markers.11 Briefly, levels of mitochondrial superoxide anion and hydrogen peroxide were measured using MitoSox Red (Invitrogen, Carlsbad, California) and 2,7′- dichlorodihydrofluorescein-diacetate (DCF-DA), respectively. The 5-Dodecanoylamino-fluorescein Di-β-D-Galactopyranoside (C12-FDG; Molecular Probes, Eugene, Oregon) was used to analyze senescence-associated β-galactosidase activity.

2.3 | Transplantation assay

To evaluate competitive repopulation activity, an equal number of PB cells in experimental groups (phosphate-buffered saline vs GO, G-CSF vs GO+G-CSF, AMD3100 vs GO+AMD3100, G-CSF +AMD3100 vs GO+G-CSF+AMD3100, and CD45.1 vs CD45.2 groups) was transplanted into lethally irradiated recipient mice (CD45.1/2, 9.5 Gy) by tail vein injection. Donor-derived PB cells were collected from recipient mice after various times of transplantation, and the ratio of CD45.1 to CD45.2 was assessed by flow cytometry. To analyze the multilineage reconstitution and self-renewal potentials of GO-mobilized HSPCs, donor-derived CD150−CD48− LK cells (CD45.2−) sorted from primary recipient mice were transplanted into conditioned secondary and tertiary recipient mice. The PB and BM of tertiary recipient mice were examined at 8 weeks post-transplantation.
2.4 | Colony-forming cell assay

Mononuclear PB (1 × 10⁶/dish) and spleen cells (5 × 10⁵/dish) were seeded into 35-mm dishes containing MethoCult GF M3434 (STEMCELL Technologies, Vancouver, Canada). Numbers of burst forming unit-erythrocyte (BFU-E), colony-forming unit-granulocyte/macrophage (CFU-GM), and colony-forming unit-granulocyte/erythroblasto/macrophage/megakaryocyte (CFU-GEMM) colonies were counted after 12 days of incubation using standard criteria.

2.5 | Blood test

PB was collected into Vacutainer (BD Biosciences) plastic tubes coated with K₂EDTA, and various types of blood cells were quantified using an automated complete cell counter (Prokan PE-6800VET). For arterial blood gas analysis, PB was also collected into 29-gauge insulin syringes (Feeltech, Gwangdeok-myeon, South Korea) without heparin, and levels of pH, O₂ saturation, PCO₂, and PO₂ were measured.

2.6 | Enzyme-linked immunosorbent assay

BM supernatant and blood serum were used to measure the concentration of stromal cell-derived factor-1 (SDF-1) using an anti-mouse ELISA kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions.

2.7 | Microcomputerized tomographic analysis

Hind limbs from ALN-treated and control mice were scanned using a desktop scanner (1076 Skyscan Micro-CT; Skyscan, Kontich, Belgium) and analyzed with CTAn software (Skyscan).

2.8 | Immunohistochemistry and tartrate-resistant acid phosphatase staining

Immunohistochemistry was performed with the Histostain Plus Anti-Rabbit or -Goat Primary DAB Kit (Zymed Laboratories) according to the manufacturer’s instructions. Briefly, the hind limbs were dissected from mice and then processed for fixation, decalcification, paraffin embedding, section (5 μm in thickness), deparaffinization, and hydration. Finally, the hydrated slides were incubated with anti-rabbit osteocalcin antibody (1:100 dilution, Takara Bio, Kyoto, Japan). Femoral bones were also fixed, decalciﬁed, embedded, and sectioned into a thickness of 5.0 μm, and the tissue sections were stained with tartrate-resistant acid phosphatase (TRAP) using a leukocyte acid phosphatase kit. Tissue sections were counterstained with hematoxylin before microscopic observation.

2.9 | Statistical analyses

All data are expressed as the mean ± SD. Student’s t test was used to determine significant differences between two sets of data, and one-way analysis of variance was used for multiple comparisons using SPSS statistical software for Windows, version 16.0 (Chicago, Illinois). A value of P < .05 was considered statistically significant.

3 | RESULTS AND DISCUSSION

3.1 | GO mobilizes long-term repopulating hematopoietic cells without adverse events

Intravenous injection of GO at 0.250 U/g, that is a concentration considered reasonably safe for clinical trials, rapidly increased DCF-positive cells in PB, but not in BM cells, in a time-dependent manner (Figure 1A). Circulating lymphoid (B220⁺ and CD3⁺) and myeloid (CD11b⁺ and Gr-1⁺) cells also exhibited a time-dependent increase in DCF-positive cells after GO injection (Figure S1A). However, numbers of circulating lymphoid and myeloid cells were differently affected, such that GO injection decreased the percentage of B220⁺ cells, but increased CD3⁺, CD11b⁺, and Gr-1⁺ cells (Figure S1B). Number of peripheral WBCs was unaffected by GO injection (Figure S1C). GO injection increased significantly the numbers of LK (P < .001) and CD150⁺/CD48⁻ LK cells (P < .05) only at 12 hours postinjection (Figure 1B), along with their relative decreases in BM (Figure S2). When the efficacy of single or consecutive injection (2-5 days) of GO to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3). PB cells collected from mice 12 hours after single GO injection revealed greater formation of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the vehicle-injected mice (Figure 1C). Similarly, spleen-conserved cells in GO-injected mice exhibited signiﬁcantly higher numbers (P < .001) of colony-forming unit cell (CFU-C) compared with the vehicle-injected mice (Figure S4). When C57BL/6 mice, a strain exhibiting a resistance to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3). PB cells collected from mice 12 hours after single GO injection revealed greater formation of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the vehicle-injected mice (Figure 1C).

2.5 | Blood test

PB was collected into Vacutainer (BD Biosciences) plastic tubes coated with K₂EDTA, and various types of blood cells were quantified using an automated complete cell counter (Prokan PE-6800VET). For arterial blood gas analysis, PB was also collected into 29-gauge insulin syringes (Feeltech, Gwangdeok-myeon, South Korea) without heparin, and levels of pH, O₂ saturation, PCO₂, and PO₂ were measured.

2.6 | Enzyme-linked immunosorbent assay

BM supernatant and blood serum were used to measure the concentration of stromal cell-derived factor-1 (SDF-1) using an anti-mouse ELISA kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions.

2.7 | Microcomputerized tomographic analysis

Hind limbs from ALN-treated and control mice were scanned using a desktop scanner (1076 Skyscan Micro-CT; Skyscan, Kontich, Belgium) and analyzed with CTAn software (Skyscan).

2.8 | Immunohistochemistry and tartrate-resistant acid phosphatase staining

Immunohistochemistry was performed with the Histostain Plus Anti-Rabbit or -Goat Primary DAB Kit (Zymed Laboratories) according to the manufacturer’s instructions. Briefly, the hind limbs were dissected from mice and then processed for fixation, decalcification, paraffin embedding, section (5 μm in thickness), deparaffinization, and hydration. Finally, the hydrated slides were incubated with anti-rabbit osteocalcin antibody (1:100 dilution, Takara Bio, Kyoto, Japan). Femoral bones were also fixed, decalciﬁed, embedded, and sectioned into a thickness of 5.0 μm, and the tissue sections were stained with tartrate-resistant acid phosphatase (TRAP) using a leukocyte acid phosphatase kit. Tissue sections were counterstained with hematoxylin before microscopic observation.

2.9 | Statistical analyses

All data are expressed as the mean ± SD. Student’s t test was used to determine significant differences between two sets of data, and one-way analysis of variance was used for multiple comparisons using SPSS statistical software for Windows, version 16.0 (Chicago, Illinois). A value of P < .05 was considered statistically significant.

3 | RESULTS AND DISCUSSION

3.1 | GO mobilizes long-term repopulating hematopoietic cells without adverse events

Intravenous injection of GO at 0.250 U/g, that is a concentration considered reasonably safe for clinical trials, rapidly increased DCF-positive cells in PB, but not in BM cells, in a time-dependent manner (Figure 1A). Circulating lymphoid (B220⁺ and CD3⁺) and myeloid (CD11b⁺ and Gr-1⁺) cells also exhibited a time-dependent increase in DCF-positive cells after GO injection (Figure S1A). However, numbers of circulating lymphoid and myeloid cells were differently affected, such that GO injection decreased the percentage of B220⁺ cells, but increased CD3⁺, CD11b⁺, and Gr-1⁺ cells (Figure S1B). Number of peripheral WBCs was unaffected by GO injection (Figure S1C). GO injection increased signiﬁcantly the numbers of LK (P < .001) and CD150⁺/CD48⁻ LK cells (P < .05) only at 12 hours postinjection (Figure 1B), along with their relative decreases in BM (Figure S2). When the efficacy of single or consecutive injection (2-5 days) of GO to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3). PB cells collected from mice 12 hours after single GO injection revealed greater formation of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the vehicle-injected mice (Figure 1C). Similarly, spleen-conserved cells in GO-injected mice exhibited signiﬁcantly higher numbers (P < .001) of colony-forming unit cell (CFU-C) compared with the vehicle-injected mice (Figure S4). When C57BL/6 mice, a strain exhibiting a resistance to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3). PB cells collected from mice 12 hours after single GO injection revealed greater formation of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the vehicle-injected mice (Figure 1C). Similarly, spleen-conserved cells in GO-injected mice exhibited signiﬁcantly higher numbers (P < .001) of colony-forming unit cell (CFU-C) compared with the vehicle-injected mice (Figure S4). When C57BL/6 mice, a strain exhibiting a resistance to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3). PB cells collected from mice 12 hours after single GO injection revealed greater formation of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the vehicle-injected mice (Figure 1C). Similarly, spleen-conserved cells in GO-injected mice exhibited signiﬁcantly higher numbers (P < .001) of colony-forming unit cell (CFU-C) compared with the vehicle-injected mice (Figure S4). When C57BL/6 mice, a strain exhibiting a resistance to mobilize LK cells was evaluated, no different effects among the injection times were found (Figure S3).
While HSPCs in PB are major source for autologous and allogeneic transplantations, use of mobilizers may increase adverse effects. G-CSF, the most widely used mobilizer in the clinic, causes side effects such as spleen enlargement, bone pain, headaches, and a propensity for thrombosis in donors. A few of patients transplanted with G-CSF-mobilized peripheral cells are also suffered from chronic-graft-vs-host disease (GVHD). The incidence of GVHD is associated with G-CSF-mediated dysregulation in the production of WBC and lymphocytes. However, our results show that GO injection does not alter components of PB cells, blood parameters, and spleen weight (Figure S6A-C). The current findings also reveal that BM numbers and senescence of LK and CD150$^+$CD48$^-$/LK cells, circulating blood cell count, and spleen weight are unchanged by GO injection in old mice even after 6 months of injection (Figure S7A-E).
In addition, GO-injected mice have life span similar to that of the vehicle-injected mice (Figure S8). Together, these results indicate that GO induces HSPC mobilization without immunological or pathological disorders. Our results also imply that GO injection neither impairs maintenance of BM HSPCs, nor causes ROS-mediated stem cell senescence. Furthermore, the result showing a normal life span of GO-injected mice supports a safety of GO in a clinical application.

3.2 GO stimulates HSPC mobilization in mice exhibiting poor mobilization and enhances the efficacy of G-CSF and AMD3100

Older individuals or patients with Fanconi anemia and impaired BM after cancer therapy exhibit poor HSPC mobilization in response to mobilizers.\textsuperscript{22,23} We investigated whether GO injection stimulates HSPC mobilization in the mice that exposed to poor mobilizing inducers or in old mice. Similar to a previous report,\textsuperscript{24} ALN injection induced osteopetrosis phenotypes showing increased bone density with decreased osteoclastic activity, while STZ highly increased blood glucose level compared with the vehicle-injected controls (Figure S9A-D). GO injection increased significantly ($P < .001$) number of LK cells in PB of the old, 5-Fu-, and ALN-treated mice, but not in STZ-treated mice, compared with the vehicle-injected controls (Figure 2A). PB cells derived from the old, 5-Fu-, or ALN-exposed mice also formed greater numbers of BFU-E, CFU-GM, and CFU-GEMM colonies compared with the control mice (Figure 2B). These results support the potential of GO to facilitate HSPC mobilization even in the mice expressing poor cell mobilization. However, our results indicate that STZ itself increases numbers of LK cells and CFU-C in PB,
and this is not affected by GO injection. Further experiments using other diabetic animals will be necessary to verify a relationship between GO treatment and diabetes.

Combined treatment of G-CSF with AMD3100 or cyclophosphamide induces synergistic effects on HSPC mobilization. Administration of G-CSF alone mobilized LK and CD150⁺CD48⁻ LK cells more than did AMD3100 only, and this was significantly (P < .01) augmented in combination with the mobilizers (Figure 2C). GO injection markedly enhanced mobilization of LK and CD150⁺CD48⁻ LK cells in the mice that received G-CSF, AMD3100, or both (Figure 2C). Competitive repopulation assay also revealed that GO injection in combination with G-CSF, AMD3100, or both significantly (P < .001) increased donor cell repopulating potential than did the mobilizer only (Figure 2D). These results support an additive mobilization effect of GO in combination regimens involving conventionally used mobilizers.

Our findings also indicate that peripheral mobilization of HSPCs in mice rapidly occurred even when treated with single GO injection like does AMD3100 rather than G-CSF.²⁸,²⁹

3.3 GO induces HSPC mobilization mainly via ROS signaling

To understand the mechanisms involved in GO-stimulated HSPC mobilization, we investigated stem cell mobilization-related factors in BM and PB. A temporal disruption of the C-X-C chemokine receptor type 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12/SDF-1) retention axis in BM induces mobilization of HSPCs into PB, and this
is a cellular mechanism of G-CSF- and AMD3100-mediated mobilization. Similar to whole BM cells (Figure 1A), DCF level in BM LK and CD150+CD45-LK cells of GO-injected mice were unchanged compared with the vehicle-injected mice (Figure S10). Compared with the vehicle-injected mice, GO-injected mice exhibited similar percentages of CXCR4+ LK and CD150+CD48-LK cells in BM and PB (Figure 3A, C), as well as SDF-1 levels in BM supernatant and blood serum throughout the postinjection times (Figure 3B, D). Activated granulocytes and monocytes in BM contribute to HSPC mobilization by increasing the production of proteolytic enzymes. While the G-CSF-injected mice showed greater numbers of Gr-1+, CD11b+, or both cells in BM, AMD3100-injected mice exhibited lower proportions of these cells compared with those in the vehicle-injected mice (Figure 3E). GO injection neither altered BM levels of Gr-1+ and CD11b+ cells, nor affected numbers of these cells regardless of combination with G-CSF or AMD3100 (Figure 3E).

Otherwise, the induction of HSPC mobilization is correlated partially with increased activity of osteoclasts. When number of osteoclasts was determined in femoral bones of GO-injected mice, no significant increase in TRAP-stained osteoclasts was found (data not shown).

Based on the mobilizing effect of GO in ALN-induced osteopetrosis mice, it is postulated that GO-induced HSPC mobilization is not associated with a signaling pathway that mediates osteoclastic activation. As GO increases oxidative stress and alters ROS-related cellular signaling, we explored whether GO-stimulated HSPC mobilization is associated with increased ROS in BM and PB along with numbers of granulocytes and osteoclasts, all of which are to be major contributors in G-CSF- and AMD3100-induced mobilization of HSPCs. Therefore, we may suggest that GO exerts its mobilizing role mainly by ROS signaling, while G-CSF- or AMD3100-induced mobilization of HSPCs is due to various cellular events derived from the SDF-1/CXCR4 axis together with ROS signaling. To clarify whether there is a specific intracellular redox molecule or ROS-unrelated pathway in GO-induced mobilization of HSPCs will be necessary. Consequently, our study indicates that the use of GO in combination with G-CSF and/or AMD3100 is to be a desirable strategy in PBSC transplantation, and the GO-related impacts on HSPC mobilization are controlled by treating antioxidant molecules.

4 | CONCLUSION

This study shows that single GO injection stimulates peripheral mobilization of HSPCs through ROS signaling and enhances synergistically the mobilizing efficacies of G-CSF and AMD3100 without adverse effects. GO-mobilized HSPCs show their reconstituting and differentiating potentials in conditioned recipients for long times. GO also stimulates HSPC mobilization even in the mice exhibiting poor stem cell mobilization. Collectively, our results provide an evidence that combined treatment of GO with commonly used mobilizers may enhance the efficacy and outcome in autologous and allogenic PBSC transplantation.

ACKNOWLEDGMENTS

The authors thank to Joshua Lee for scientific editing of the manuscript. This work was supported by the National Research Foundation of Korea funded by the Ministry of Science, Information and Communications Technology and Future Planning, Republic of Korea (2019R1A2C2084453 and 2021R1A2C2006032).

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

J.-C.L.: conceived and designed the experiments, contributed reagents, materials, and analytical tools, wrote and/or edited the manuscript; S.-H. K.: conceived and designed the experiments, performed the experiments and analyzed the data, contributed reagents, materials, and analytical tools, wrote and/or edited the manuscript; H.-S.S.: performed the experiments and analyzed the data, wrote and/or edited the manuscript; M.-G. K.: performed the experiments and analyzed the data.

DATA AVAILABILITY STATEMENT

The data used to support the findings of this study are available from the corresponding author upon request.

ORCID

Jeong-Chae Lee https://orcid.org/0000-0002-4340-7965
Sung-Ho Kook https://orcid.org/0000-0002-1879-5927

REFERENCES

1. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med. 1997;126:600-607.
2. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588-596.
3. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood. 1993;81:1960-1967.
4. Tesio M, Golan K, Corso S, et al. Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood. 2011;117:419-428.
SINGLE GO INJECTION-INDUCED MOBILIZATION OF HSPCs

5. Dar A, Schajnovitz A, Lapid K, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. *Leukemia*. 2011;25:1286-1296.

6. Lennnicke C, Rahn J, Lichtenfels R. Hydrogen peroxide—production, fate and in redox signaling of tumor cells. *Cell Commun Signal*. 1993;13:39.

7. Choe Y, Yu JY, Son YO, et al. Continuously generated H2O2 stimulates the proliferation and osteoblastic differentiation of human periodontal ligament fibroblasts. *J Cell Biochem*. 2012;113:1426-1436.

8. Sim HJ, Kim JH, Kook SH, Lee SY, Lee JC. Glucose oxidase facilitates osteogenic differentiation and mineralization of embryonic stem cells through the activation of Nr2 and ERK signal transduction pathways. *Mol Cell Biochem*. 2016;419:157-163.

9. Dubey MK, Zehra A, Aamir M, et al. Improvement strategies, cost effective production, and potential applications of fungal glucose oxidase (GOD): current updates. *Front Microbiol*. 2017;8:1032-1053.

10. Fadini GP, Fiala M, Cappellari R, et al. Diabetes limits stem cell mobilization following G-CSF but not plerixafor. *Diabetes*. 2015;64:2969-2977.

11. Bhattarai CL, Liang R, Ghaffari S. Stem cells and the impact of ROS signaling. *Development*. 2014;141:4206-4218.

12. Bigarella CL, Kook SH, Kim JH, et al. COMP-Ang1 prevents periodontitis and enhances mandible bone growth in an experimental animal model. *Bone*. 2016;92:168-179.

13. Samoszuk M, Ehrlich D, Ramzi E. Preclinical safety studies of glucose oxidase. *J Pharmacol Exp Ther*. 1993;266:1643-1648.

14. van de Rijn M, Heimfeld S, Spangrude GJ, Weissman IL. Mouse hematopoietic stem-cell antigen Scä-1 is a member of the Ly-6 antigen family. *Proc Natl Acad Sci USA*. 1989;86:4634-4638.

15. Roberts AW, Foote S, Alexander WS, Scott C, Robb L, Metcalf D. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. *Blood*. 1997;89:2736-2744.

16. Majolino I, Aversa F, Baccigalupo A, et al. Allogeneic transplants of rhG-CSF-mobilized peripheral blood stem cells (PBSC) from normal donors. *Haematologica*. 1995;80:40-43.

17. Platzbecker U, Prange-Krex G, Bornhauser M, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. *Transfusion*. 2001;41:184-189.

18. Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. *Blood*. 2010;116:819-828.

19. Li JM, Giver CR, Lu Y, Hossain MS, Akhtari M, Waller EK. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. *Immunotherapy*. 2009;1:599-621.

20. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. *Immunotherapy*. 2009;1:599-621.

21. Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. *Best Pract Res Clin Haematol*. 2008;21:205-222.

22. Pulliam AC, Hobson MJ, Ciccone SL, et al. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. *Exp Hematol*. 2008;36:1084-1090.

23. D’Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. *Bone Marrow Transplant*. 2011;46:356-363.

24. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells definitions, incidence, risk factors, and impact on outcome of autologous transplantation. *Biol Blood Marrow Transplant*. 2010;16:490-499.

25. Levesque JP, Hendy J, Takamatsu Y, et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. *Exp Hematol*. 2002;30:440-449.

26. Kollet O, Dar A, Shitviel S, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. *Nat Med*. 2006;12:657-664.

27. Wright DE, Cheshier SH, Wagers AJ, Randall TD, Christensen JL, Weissman IL. Cyclophosphamide/granulocyte colony stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. *Blood*. 2001;97:2278-2285.

28. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med*. 2005;201:1307-1318.

29. Petit I, Syzpyr-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat Immunol*. 2002;3:687-694.

30. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science*. 1999;283:845-848.

31. Kook SH, Cho JS, Lee SB, Lee BC. The nucleotide sugar UDP-glucose mobilizes long term repopulating primitive hematopoietic cells. *J Clin Invest*. 2013;123:3420-3435.

32. Singh P, Hu P, Hoggatt J, Moh A, Pelus LM. Expansion of bone marrow neutrophils following G-CSF administration in mice results in osteolineage cell apoptosis and mobilization of hematopoietic stem and progenitor cells. *Leukemia*. 2012;26:2375-2383.

33. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. *J Clin Invest*. 2003;111:187-196.

34. Hirbe AC, Uluckan O, Morgan EA, et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. *Blood*. 2007;109:3424-3431.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: So H-S, Kim M-G, Lee J-C, Kook S-H. Glucose oxidase induces mobilization of long-term repopulating hematopoietic cells in mice. *STEM CELLS Transl Med*. 2021;10(10):1446-1453. [https://doi.org/10.1002/sctm.20-0514](https://doi.org/10.1002/sctm.20-0514)